| scholarly article | Q13442814 |
| P50 | author | Stefanie Sarantopoulos | Q62050367 |
| Bruce R Blazar | Q62070764 | ||
| Joseph H Antin | Q89778009 | ||
| Jerome Ritz | Q41590860 | ||
| P2093 | author name string | Corey Cutler | |
| Jacalyn Rosenblatt | |||
| Edwin Alyea | |||
| Robert J Soiffer | |||
| Yi-Bin Chen | |||
| Haesook T Kim | |||
| John Koreth | |||
| Philippe Armand | |||
| Vincent T Ho | |||
| Brett Glotzbecker | |||
| Phandee Watanaboonyongcharoen | |||
| Sean McDonough | |||
| Bhavjot Bindra | |||
| P2860 | cites work | Administration of cyclosporine for 24 months compared with 6 months for prevention of chronic graft-versus-host disease: a prospective randomized clinical trial | Q43423459 |
| Serious graft-versus-host disease after hematopoietic cell transplantation following nonmyeloablative conditioning | Q43526119 | ||
| CD19(+)CD21(low) B cells and patients at risk for NIH-defined chronic graft-versus-host disease with bronchiolitis obliterans syndrome. | Q44030095 | ||
| Genetic variation in recipient B-cell activating factor modulates phenotype of GVHD. | Q53243966 | ||
| Chronic graft-versus-host disease | Q56340012 | ||
| B-cell involvement in chronic graft-versus-host disease | Q57676591 | ||
| One-year cyclosporine prophylaxis reduces the risk of developing extensive chronic graft-versus-host disease after allogeneic peripheral blood stem cell transplantation | Q73159060 | ||
| CD6+ donor marrow T-cell depletion as the sole form of graft-versus-host disease prophylaxis in patients undergoing allogeneic bone marrow transplant from unrelated donors | Q73446829 | ||
| Anti-CD20 monoclonal antibody treatment in 6 patients with therapy-refractory chronic graft-versus-host disease | Q80337229 | ||
| Rituximab as salvage therapy for refractory chronic GVHD | Q80709875 | ||
| Protective conditioning for acute graft-versus-host disease | Q81279975 | ||
| Rituximab is effective for steroid-refractory sclerodermatous chronic graft-versus-host disease | Q81381423 | ||
| In vivo B-cell depletion with rituximab for alternative donor hemopoietic SCT | Q83772197 | ||
| Long-term follow-up of myeloablative allogeneic stem cell transplantation using Campath "in the bag" as T-cell depletion: the Leiden experience | Q83939614 | ||
| Antibody responses to H-Y minor histocompatibility antigens correlate with chronic graft-versus-host disease and disease remission | Q24539030 | ||
| Regression modeling of competing risks data based on pseudovalues of the cumulative incidence function | Q30983769 | ||
| Allogeneic peripheral blood stem-cell compared with bone marrow transplantation in the management of hematologic malignancies: an individual patient data meta-analysis of nine randomized trials | Q30997153 | ||
| Treatment of refractory chronic GVHD with rituximab: a GITMO study. | Q33375484 | ||
| Endpoints for clinical trials testing treatment of acute graft-versus-host disease: a joint statement | Q33622648 | ||
| Patient-reported quality of life is associated with severity of chronic graft-versus-host disease as measured by NIH criteria: report on baseline data from the Chronic GVHD Consortium | Q33830644 | ||
| Characterization of a rare IL-10-competent B-cell subset in humans that parallels mouse regulatory B10 cells. | Q34144779 | ||
| Rituximab administration within 6 months of T cell-depleted allogeneic SCT is associated with prolonged life-threatening cytopenias. | Q34164140 | ||
| Acute and chronic graft-versus-host disease after allogeneic peripheral-blood stem-cell and bone marrow transplantation: a meta-analysis | Q34337007 | ||
| National Institutes of Health consensus development project on criteria for clinical trials in chronic graft-versus-host disease: I. Diagnosis and staging working group report | Q34474243 | ||
| Thymoglobulin prevents chronic graft-versus-host disease, chronic lung dysfunction, and late transplant-related mortality: long-term follow-up of a randomized trial in patients undergoing unrelated donor transplantation | Q34517135 | ||
| Recovery of B-cell homeostasis after rituximab in chronic graft-versus-host disease | Q34707354 | ||
| Standard graft-versus-host disease prophylaxis with or without anti-T-cell globulin in haematopoietic cell transplantation from matched unrelated donors: a randomised, open-label, multicentre phase 3 trial | Q34998580 | ||
| Global and organ-specific chronic graft-versus-host disease severity according to the 2005 NIH Consensus Criteria | Q35483810 | ||
| The global severity of chronic graft-versus-host disease, determined by National Institutes of Health consensus criteria, is associated with overall survival and non-relapse mortality | Q35528671 | ||
| Donor B-cell alloantibody deposition and germinal center formation are required for the development of murine chronic GVHD and bronchiolitis obliterans | Q35776453 | ||
| Rituximab for steroid-refractory chronic graft-versus-host disease | Q35848933 | ||
| Impact of chronic graft-versus-host disease on the health status of hematopoietic cell transplantation survivors: a report from the Bone Marrow Transplant Survivor Study | Q35849241 | ||
| Prophylactic rituximab after allogeneic transplantation decreases B-cell alloimmunity with low chronic GVHD incidence | Q36057911 | ||
| A disease risk index for patients undergoing allogeneic stem cell transplantation | Q36141944 | ||
| B cells from patients with chronic GVHD are activated and primed for survival via BAFF-mediated pathways | Q36250962 | ||
| Advances in human B cell phenotypic profiling | Q36307080 | ||
| National Institutes of Health Consensus Development Project on Criteria for Clinical Trials in Chronic Graft-versus-Host Disease: VI. Design of Clinical Trials Working Group report | Q36458844 | ||
| National Institutes of Health chronic graft-versus-host disease staging in severely affected patients: organ and global scoring correlate with established indicators of disease severity and prognosis. | Q36747224 | ||
| Bone marrow B cell precursor number after allogeneic stem cell transplantation and GVHD development | Q36956851 | ||
| HLA-haploidentical bone marrow transplantation for hematologic malignancies using nonmyeloablative conditioning and high-dose, posttransplantation cyclophosphamide | Q37078261 | ||
| Altered B-cell homeostasis and excess BAFF in human chronic graft-versus-host disease | Q37162874 | ||
| Efficacy of rituximab in the setting of steroid-refractory chronic graft-versus-host disease: a systematic review and meta-analysis | Q37574510 | ||
| The role of B cells in the pathogenesis of graft-versus-host disease | Q37596195 | ||
| Effector and regulatory B cells: modulators of CD4+ T cell immunity | Q37708012 | ||
| Normal B cell homeostasis requires B cell activation factor production by radiation-resistant cells | Q42079747 | ||
| P433 | issue | 8 | |
| P407 | language of work or name | English | Q1860 |
| P921 | main subject | rituximab | Q412323 |
| phase II clinical trial | Q42824440 | ||
| stem cell transplantation | Q65592366 | ||
| P304 | page(s) | 1510-1517 | |
| P577 | publication date | 2013-07-16 | |
| P1433 | published in | Blood | Q885070 |
| P1476 | title | Rituximab prophylaxis prevents corticosteroid-requiring chronic GVHD after allogeneic peripheral blood stem cell transplantation: results of a phase 2 trial | |
| P478 | volume | 122 |
| Q35218515 | A phase II study of a nonmyeloablative allogeneic stem cell transplant with peritransplant rituximab in patients with B cell lymphoid malignancies: favorably durable event-free survival in chemosensitive patients |
| Q35737769 | A phase II study of bortezomib plus prednisone for initial therapy of chronic graft-versus-host disease |
| Q40115697 | A review of late complications of allogeneic hematopoietic stem cell transplantations |
| Q35171251 | Aberrant B-cell homeostasis in chronic GVHD |
| Q94487283 | Addition of anti-thymocyte globulin to standard graft-versus-host disease prophylaxis |
| Q33905411 | Administration of anti-CD20 mAb is highly effective in preventing but ineffective in treating chronic graft-versus-host disease while preserving strong graft-versus-leukemia effects |
| Q35586614 | Advances and challenges in immunotherapy for solid organ and hematopoietic stem cell transplantation |
| Q35607308 | Allogeneic HY antibodies detected 3 months after female-to-male HCT predict chronic GVHD and nonrelapse mortality in humans. |
| Q47402442 | Antibodies targeting surface membrane antigens in patients with chronic graft-versus-host disease |
| Q36891433 | Approaches for the prevention of graft-versus-host disease following hematopoietic cell transplantation |
| Q26861706 | B cells in chronic graft-versus-host disease |
| Q50044417 | B-cell targeting in chronic Graft-versus-Host disease |
| Q91931325 | Can we use interleukin-6 (IL-6) blockade for coronavirus disease 2019 (COVID-19)-induced cytokine release syndrome (CRS)? |
| Q49900740 | Chronic Graft-versus-Host Disease: A Long Road Ahead |
| Q39002164 | Chronic graft-versus-host disease: biological insights from preclinical and clinical studies |
| Q36920466 | Circulating T follicular helper cells with increased function during chronic graft-versus-host disease |
| Q35235186 | Clinical impact of H-Y alloimmunity |
| Q93188328 | Comprehensive B Cell Phenotyping Profile for Chronic Graft-versus-Host Disease Diagnosis |
| Q27016541 | Current and emerging strategies for the prevention of graft-versus-host disease |
| Q33917187 | Current issues in chronic graft-versus-host disease |
| Q92095447 | Dissecting the biology of allogeneic HSCT to enhance the GvT effect whilst minimizing GvHD |
| Q50143234 | Effect of Rituximab on Pulmonary Function in Bronchiolitis Obliterans Syndrome due to Graft-Versus-Host-Disease |
| Q38786084 | Emerging drugs for graft-versus-host disease |
| Q48573554 | Fludarabine and Busulfan versus Fludarabine, Cyclophosphamide, and Rituximab as Reduced-Intensity Conditioning for Allogeneic Transplantation in Follicular Lymphoma |
| Q27012940 | Graft-versus-host disease: why have we not made more progress? |
| Q58782275 | How ibrutinib, a B-cell malignancy drug, became an FDA-approved second-line therapy for steroid-resistant chronic GVHD |
| Q42203241 | In vitro effects of different 8-methoxypsoralen treatment protocols for extracorporeal photopheresis on mononuclear cells |
| Q40042286 | Long-term outcome of Epstein-Barr virus DNAemia and PTLD with the use of preemptive rituximab following allogeneic HSCT. |
| Q34860077 | Low-dose antithymocyte globulin enhanced the efficacy of tacrolimus and mycophenolate for GVHD prophylaxis in recipients of unrelated SCT. |
| Q34769213 | Managing high-risk CLL during transition to a new treatment era: stem cell transplantation or novel agents? |
| Q39002166 | Mechanistic approaches for the prevention and treatment of chronic GVHD. |
| Q52897641 | Monitoring the kinetics of B-cell recovery following rituximab may guide the management of steroid-refractory chronic GvHD. |
| Q49238507 | New and emerging therapies for acute and chronic graft versus host disease |
| Q39023963 | Novel targets in the treatment of chronic graft-versus-host disease |
| Q41387926 | Ofatumumab in combination with glucocorticoids for primary therapy of chronic graft-versus-host disease: phase I trial results |
| Q36264895 | Phase II Study of Nonmyeloablative Allogeneic Bone Marrow Transplantation for B Cell Lymphoma with Post-Transplantation Rituximab and Donor Selection Based First on Non-HLA Factors. |
| Q101133415 | Post-transplantation cyclophosphamide restores early B-cell lymphogenesis that suppresses subsequent chronic graft-versus-host disease |
| Q38753771 | Potential of glycosylation research in graft versus host disease after allogeneic hematopoietic stem cell transplantation |
| Q41179451 | Preferential depletion of host over donor T cells through in vivo decay of active rabbit-anti-thymocyte globulin levels during reduced intensity conditioning |
| Q45325606 | Protective Effect of Rituximab in Chronic Graft-Versus-Host Disease Occurrence in Allogeneic Transplant patients with Epstein Barr Virus Viremia |
| Q38246755 | Recent advances on cellular therapies and immune modulators for graft-versus-host disease |
| Q89304322 | Reduced-Intensity Conditioning with Fludarabine, Cyclophosphamide, and High-Dose Rituximab for Allogeneic Hematopoietic Cell Transplantation for Follicular Lymphoma: A Phase Two Multicenter Trial from the Blood and Marrow Transplant Clinical Trials |
| Q52880975 | Risk of graft-versus-host disease with rituximab-containing conditioning regimens in allogeneic hematopoietic stem cell transplant. |
| Q87874816 | Rituximab after lymphoma-directed conditioning and allogeneic stem-cell transplantation for relapsed and refractory aggressive non-Hodgkin lymphoma (DSHNHL R3): an open-label, randomised, phase 2 trial |
| Q33792160 | Rituximab-containing reduced-intensity conditioning improves progression-free survival following allogeneic transplantation in B cell non-Hodgkin lymphoma |
| Q57029315 | SYK inhibitor entospletinib prevents ocular and skin GVHD in mice |
| Q90289034 | Safety and efficacy of rituximab-based first line treatment of chronic GVHD |
| Q35784522 | Targeting Syk-activated B cells in murine and human chronic graft-versus-host disease |
| Q28076264 | The Biology of Chronic Graft-versus-Host Disease: A Task Force Report from the National Institutes of Health Consensus Development Project on Criteria for Clinical Trials in Chronic Graft-versus-Host Disease |
| Q52971841 | The Role of B Cell Targeting in Chronic Graft-Versus-Host Disease. |
| Q49384876 | The Role of Janus Kinase Signaling in Graft-Versus-Host Disease and Graft Versus Leukemia. |
| Q38392246 | Therapeutic benefits targeting B-cells in chronic graft-versus-host disease |
| Q64063450 | Transplant-Associated Thrombotic Microangiopathy in Pediatric Hematopoietic Cell Transplant Recipients: A Practical Approach to Diagnosis and Management |
| Q93106889 | Worldwide Network for Blood and Marrow Transplantation (WBMT) perspective: the role of biosimilars in hematopoietic cell transplant: current opportunities and challenges in low- and lower-middle income countries |
| Q87291596 | [Progress of chronic graft-versus-host disease] |
Search more.